Intuitive Surgical Posts Higher Revenue, Operating Income, Net Income, and Diluted EPS Year-Over-Year on Both Reporting Windows

Bottom line

INTUITIVE SURGICAL INC delivered a higher top line and deeper profitability on both reporting windows in this filing. Revenue from Contract with Customer, Excluding Assessed Tax was $2,892,300,000 USD for the three months ended June 30, 2026 and $5,663,100,000 USD for the six months ended June 30, 2026, both higher than the prior-year comparative levels of $2,440,000,000 USD for the three months ended June 30, 2025 and $4,693,400,000 USD for the six months ended June 30, 2025. Operating Income (Loss) reached $971,900,000 USD for the three months ended June 30, 2026 and $1,827,200,000 USD for the six months ended June 30, 2026, both higher than $743,400,000 USD for the three months ended June 30, 2025 and $1,321,500,000 USD for the six months ended June 30, 2025. Net Income (Loss) Attributable to Parent was $818,100,000 USD for the three months ended June 30, 2026 and $1,639,600,000 USD for the six months ended June 30, 2026, both higher than $658,400,000 USD for the three months ended June 30, 2025 and $1,356,800,000 USD for the six months ended June 30, 2025, and each period remained a profit, matching the profit classification of the prior year. Earnings Per Share, Diluted printed $2.29 per diluted share USD/SHARES for the three months ended June 30, 2026 and $4.57 per diluted share USD/SHARES for the six months ended June 30, 2026, each higher than the prior-year comparatives of $1.81 per diluted share USD/SHARES and $3.72 per diluted share USD/SHARES, again with profit-to-profit continuity. The filing evidence does not attribute this change to any single cause.

The reporting window covered here is the 10-Q for period-ended-2026-06-30 of INTUITIVE SURGICAL INC (ticker ISRG, CIK 0001035267), submitted under accession 0001035267-26-000058. The figures above are the unaudited condensed consolidated results for the three-month and six-month year-to-date reporting windows and their prior-year comparatives as presented in the filing's condensed consolidated statements and the related footnote disclosures, with revenue recognition and contract asset context addressed in Note 7. Source scope is limited to the unaudited condensed consolidated financial statements and the accompanying notes supplied in this filing; no peer or industry comparison is provided in the filing evidence. The filing evidence contains no peer or industry comparison. A nearby Lizely Finance Earnings Analysis of UFP TECHNOLOGIES INC interim filing applies a similar profit-to-profit framework to a different issuer and may help readers calibrate the wording used here.

Financial performance

INTUITIVE SURGICAL INC ISRG filed the 10-Q for period-ended-2026-06-30 under accession 0001035267-26-000058. The financial statements cover the three-month reporting period at the three months ended June 30, 2026 and the six-month year-to-date period at the six months ended June 30, 2026, each shown against the prior-year comparatives at the three months ended June 30, 2025 and the six months ended June 30, 2025. Together these two windows set the year-over-year and quarter-over-quarter baselines used throughout this section. The filing notes that interim results "are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods," a standard cautionary framing that this section adopts as-is.

On the top line, revenue reads against both windows: $2,892,300,000 USD for the three months ended June 30, 2026 versus $2,440,000,000 USD for the three months ended June 30, 2025, and $5,663,100,000 USD for the six months ended June 30, 2026 versus $4,693,400,000 USD for the six months ended June 30, 2025. The authorized comparison registers a higher level in each case. Operating income follows the same pattern: $971,900,000 USD for the three months ended June 30, 2026 against $743,400,000 USD for the three months ended June 30, 2025, and $1,827,200,000 USD for the six months ended June 30, 2026 against $1,321,500,000 USD for the six months ended June 30, 2025, again with the authorized comparison reading as higher in each pair. Net income attributable to parent tracks the same shape: $818,100,000 USD for the three months ended June 30, 2026 against $658,400,000 USD for the three months ended June 30, 2025, and $1,639,600,000 USD for the six months ended June 30, 2026 versus $1,356,800,000 USD for the six months ended June 30, 2025, with the authorized comparison reading higher. Diluted earnings per share likewise register higher against the authorized comparison on both windows: $2.29 per diluted share USD/SHARES for the three months ended June 30, 2026 versus $1.81 per diluted share USD/SHARES for the three months ended June 30, 2025, and $4.57 per diluted share USD/SHARES for the six months ended June 30, 2026 versus $3.72 per diluted share USD/SHARES for the six months ended June 30, 2025. Each authorized transition is profit to profit.

Quarter-over-quarter the half-year totals sit above the three-month period on revenue, operating income, net income and diluted EPS, consistent with the natural accumulation of six months versus a single quarter. No quarter-over-quarter percentage is stated here; the relationship is described qualitatively only. Management flags macroeconomic and geopolitical risks including tariffs and trade barriers, inflationary pressures, elevated interest rates, commodity-market disruptions from conflicts, and supply-chain constraints on supplier capacity and critical materials. The filing evidence does not attribute this change to any single cause.

On accounting context, the filing discloses recently adopted and recently issued pronouncements. The Company adopted the credit-losses practical expedient for current accounts receivable and current contract assets and reports that adoption did not have a material impact. It is evaluating two further pronouncements that touch expense disaggregation disclosures and internal-use software accounting; neither has a stated effective impact yet. Investments are classified into fair-value tiers, with the cited note mapping money-market funds to Level 1 and corporate debt securities to Level 2. The segment of available-for-sale debt securities discussed in Note 8 and the contract-asset presentation described in Note 7 frame the supporting disclosure environment. The filing evidence contains no peer or industry comparison.

Operating drivers and segments

- The filing under 10-Q period-ended-2026-06-30 (accession 0001035267-26-000058) does not present discrete, separately-reported operating segments; the description of the business defines two product families — da Vinci surgical systems for general, urologic, gynecologic, cardiothoracic, and head-and-neck surgery, and the Ion endoluminal system used for minimally invasive lung biopsies — under which revenue is reported as a single consolidated line, Revenue from Contract with Customer, Excluding Assessed Tax. - That single-line revenue rose year over year on both windows the filing presents: for the three months ended June 30, 2026, Revenue from Contract with Customer, Excluding Assessed Tax was $2,892,300,000 USD, higher than the prior-year the three months ended June 30, 2025 reading of $2,440,000,000 USD; for the the six months ended June 30, 2026 YTD window, Revenue from Contract with Customer, Excluding Assessed Tax was $5,663,100,000 USD, higher than the prior-year the six months ended June 30, 2025 figure of $4,693,400,000 USD. - Operating income expanded in parallel: for the three months ended June 30, 2026, Operating Income (Loss) was $971,900,000 USD, higher than the prior-year the three months ended June 30, 2025 figure of $743,400,000 USD; for the six months ended June 30, 2026, Operating Income (Loss) was $1,827,200,000 USD, higher than the prior-year the six months ended June 30, 2025 figure of $1,321,500,000 USD, with the prior-period to current-period transition being profit to profit in both windows. - Because segment-level revenue, cost, and margin detail are not broken out in the cited evidence, any product-family level margin differential, or a per-region view, cannot be verified from the filing alone. The filing evidence contains no peer or industry comparison.

The filing evidence does not attribute this change to any single cause. Management's narrative addresses risks and uncertainties — tariff changes, supplier pass-through of tariff-related costs, inflationary pressures, elevated interest rates, ongoing conflicts and their supply-chain implications — but these are forward-looking risk statements, not an attribution of observed revenue or operating-income change to a specific driver. The recently adopted ASU on credit losses is described as not having a material impact, and no inside-the-period causal walkthrough of revenue, mix, or operating leverage is offered in the quoted text. Readers should therefore treat the cited revenue and operating-income growth as recorded results and not as management-explained growth. For a cross-check on how a peer robotics-and-platform reporter framed year-over-year growth against analyst expectations in the same release window, see Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in the reporting period Filing.

- Authorised directional checks for context, drawn from a different filing window, appear in Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows.

Cash flow and capital

- The half-year cash flow picture for INTUITIVE SURGICAL INC (filed as 10-Q for period-ended-2026-06-30, accession 0001035267-26-000058) shows a mixed directional pattern across the three activity buckets versus the prior-year comparative the six months ended June 30, 2025. Operating activities remained the cash engine, generating a positive inflow of $1,972,900,000 versus $1,297,000,000 — directionally higher year over year, consistent with the revenue and net-income growth highlighted earlier in this analysis. Investing activities swung from a positive $474,200,000 to a negative -$941,100,000, signaling a re-deployment of liquidity into the available-for-sale debt portfolio rather than net divestitures.

Financing activities stayed negative on both sides of the comparison (-$383,600,000 and -$1,641,600,000), with the more recent six-month period registering a larger outflow than the prior year — directionally deeper as a use of cash. - Management's framing of the investing line, drawn from the fair-value and maturities discussion, explains the portfolio mechanics behind that swing. The contractual-maturity schedule shows the bulk of cash equivalents and available-for-sale debt securities (excluding money market funds) sitting in the less-than-one-year bucket as of the balance sheet date of June 30, 2026, with the remainder in the one-to-five-year range, and unrealized-loss aging is split between the under-twelve-month and twelve-month-or-greater tiers.

S. Treasuries (citing sovereign guarantee, reserve-currency status, and historical credit performance), with corporate debt holdings similarly anchored in high-quality issuers. The unrealized-loss commentary supports the read that the investing-flow swing reflects fresh purchases rather than a forced sale.

The filing evidence does not attribute this change to any single cause. - Capital returns to shareholders remain the dominant financing use. Common-stock repurchases rose to $1,443,500,000 from $181,000,000 in the prior-year six-month window — directionally higher — which lines up with the larger financing outflow and is consistent with the share-count math feeding the diluted EPS gain covered earlier.

No other return-of-capital line is sized in the filing evidence. - The balance sheet at the balance sheet date of June 30, 2026 is presented in compact form: cash and cash equivalents of $2,760,400,000, accounts receivable (after the allowance for credit loss) of $1,673,200,000, and accounts payable of $277,200,000. Working-capital intensity is not separately quantified here, and the receivables and payable balances sit alongside the operating cash generation noted above.

- The hedging program disclosed in the filing — currency forwards against EUR, JPY, KRW, GBP, TWD, INR, CAD revenue exposure and CHF/EUR expense exposure, plus a balance-sheet hedge book — adds a context layer for translating the operating cash figure, though it is not separately quantified in dollar terms. Reader-facing context for cross-checking operating-cash interpretation against a peer pattern is available in the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing companion note.

Segment-level detail for the cash flow and balance-sheet lines is not disclosed in this report. The filing evidence does not disclose segment-level detail for this dimension.

Peer and historical context

Looking across the two reporting windows in this 10-Q filing from INTUITIVE SURGICAL INC (ISRG, CIK 0001035267, accession 0001035267-26-000058), the year-over-year trend line is consistent across every line item the catalog authorizes. Revenue from contracts with customers was $2,892,300,000 USD for the three months ended June 30, 2026 versus $2,440,000,000 USD for the three months ended June 30, 2025, and on a six-month basis the line expanded from $4,693,400,000 USD for the six months ended June 30, 2025 to $5,663,100,000 USD for the six months ended June 30, 2026, in each case an authorized increase against the prior-year comparative. Operating Income tracked in the same direction, advancing from $743,400,000 USD to $971,900,000 USD on the three-month window and from $1,321,500,000 USD to $1,827,200,000 USD on the six-month window, with the current and prior periods remaining profitable throughout. Net Income attributable to parent followed that path, rising from $658,400,000 USD to $818,100,000 USD for the quarter and from $1,356,800,000 USD to $1,639,600,000 USD for the half year, preserving a profit-to-profit transition on both windows. The cash-flow statement reinforces the income-statement picture: net cash provided by operating activities was $1,297,000,000 USD for the six months ended June 30, 2025 and expanded to $1,972,900,000 USD for the six months ended June 30, 2026, with current and prior both positive and the authorized direction reading as an increase. Against a backdrop in which peer or industry comparison is absent from the filing evidence, this is essentially a self-comparison: every line that the catalog authorizes as an increase versus the prior year actually is one, and no authorized line contradicts that pattern. Broader cross-issuer context is limited to other Lizely Finance coverage of similarly structured filings, such as the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing write-up, which frames the same revenue and operating-income pattern in a different name. The quarter-over-half-year progression inside this filing is also worth noting, since the six-month aggregates are simply larger than the three-month prints without altering direction.

A few items in the source narrative temper any purely celebratory read. The filing discusses unrealized losses on available-for-sale debt securities, hedging of foreign-currency-denominated revenue and expenses, and remaining performance obligations tied to system sale, lease and service arrangements that stretch several years into the future, but it does not quantify peer or industry benchmarks. Any gap between this issuer and a named peer cannot be sized here.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension.

Scenario analysis

For INTUITIVE SURGICAL INC in the 10-Q covering the three months ended June 30, 2026 and the six months ended June 30, 2026, the base case mirrors the comparative path actually reported. Revenue from Contract with Customer, Excluding Assessed Tax in the three months ended June 30, 2026 reads $2,892,300,000 USD, higher than the prior-year quarter reading of $2,440,000,000 USD, and the six-month window posts $5,663,100,000 USD, higher than the $4,693,400,000 USD prior-year mark. Net Income (Loss) Attributable to Parent lands at $818,100,000 USD for the three months ended June 30, 2026 versus $658,400,000 USD a year earlier, with the year-to-date picture of $1,639,600,000 USD against $1,356,800,000 USD. Operating Income (Loss) stays profitable on both windows, and Earnings Per Share, Diluted moves from profit to profit at higher levels on each window. Operating cash flow remains positive on a higher base than the prior year, financing cash outflow is wider, and investing cash flow has shifted from a positive prior-year inflow to a current-period use. In the base case, procedure volume, system placements, and recurring service revenue continue to expand at a pace consistent with the year-to-date run rate.

The upside rests on the same trend lines accelerating rather than merely extending. Revenue from Contract with Customer, Excluding Assessed Tax grows faster than the gap already implied by $2,892,300,000 USD versus $2,440,000,000 USD and $5,663,100,000 USD versus $4,693,400,000 USD, supported by the multi-currency hedging program covering EUR, JPY, KRW, GBP, TWD, INR, CAD, and CHF exposures and by the remaining performance obligations described in the cited note, roughly half of which are expected to be recognized in the near term with the balance recognized over the longer-term system, lease, and service arrangement horizon. Operating Income (Loss) widens alongside, Net Income (Loss) Attributable to Parent lifts further from $818,100,000 USD and $1,639,600,000 USD, and Earnings Per Share, Diluted extends the profit-to-profit increase. A larger Payments for Repurchase of Common Stock figure versus the prior-year period remains consistent with the higher operating cash generation that an upside delivers. Readers comparing this trajectory with peer quarterly prints can also review Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing for a contrasting profit-to-profit growth pattern.

The downside contemplates a slowdown without a swing to loss. Revenue from Contract with Customer, Excluding Assessed Tax flattens relative to the $2,440,000,000 USD and $4,693,400,000 USD bases, leaving the $2,892,300,000 USD and $5,663,100,000 USD readings as the high-water mark. The multi-currency hedging program tied to revenue in EUR, JPY, KRW, GBP, TWD, INR, CAD, and CHF would translate weaker top-line momentum into compressed earnings, and Net Income (Loss) Attributable to Parent slips from $818,100,000 USD and $1,639,600,000 USD while still staying positive, much as Net Cash Provided by (Used in) Investing Activities has flipped from positive cash inflow in the prior year to a use of cash in the current period. Accretion (Amortization) of Discounts and Premiums, Investments is also smaller than the prior year on the six-month comparison, a quiet drag on the investment portfolio contribution. The filing evidence does not attribute this change to any single cause.

Macro and policy pressures called out in the cited note — inflation, tariffs, high interest rates, staffing shortages, healthcare laws, and reimbursement changes — could weigh on hospital cash flows, lengthen receivable collection, and cap the appetite for new system placements, but no peer benchmark exists in the filing evidence. The filing evidence contains no peer or industry comparison. Operating segment detail beyond geographic revenue is also not separately disclosed, so the path to any downside landing remains tied to the company-wide rather than business-line mix. The filing evidence does not disclose segment-level detail for this dimension.

Risks and what to watch

- Revenue increased year over year to $2,892,300,000 in the three months ended June 30, 2026, compared with $2,440,000,000 in the three months ended June 30, 2025. Revenue also increased on the year-to-date view to $5,663,100,000 in the six months ended June 30, 2026, versus $4,693,400,000 in the six months ended June 30, 2025. This is favorable counter-evidence to a demand slowdown, although the filing does not separate procedure volumes, system placements, service activity, pricing, or mix.

- Net income attributable to the parent increased to $818,100,000 in the three months ended June 30, 2026, from $658,400,000 in the three months ended June 30, 2025. The year-to-date comparison likewise increased to $1,639,600,000 in the six months ended June 30, 2026, compared with $1,356,800,000 in the six months ended June 30, 2025. Both periods remained profitable, so the current evidence does not show a loss-making outcome.

- The main operating risk is the sensitivity of hospitals and other customers to healthcare regulation, procedure coverage and reimbursement, economic conditions, inflation, tariffs, high interest rates, staffing shortages, and broader recessionary pressure. Management states that these factors could weaken hospital cash flows and increase customer credit risk. - The allowance for doubtful accounts is reviewed using historical experience, credit quality, receivable aging, and prevailing economic conditions.

Bad-debt expense was not material for either the quarterly or year-to-date periods presented, and the company historically has not experienced significant credit losses. That record is reassuring, but it does not eliminate exposure if customer finances deteriorate. - A meaningful portion of remaining performance obligations relates to future service under system sale and lease arrangements.

Approximately half are expected to be recognized in the near term, with the remainder recognized over the arrangement term. This supports future revenue visibility, while the recognition pattern remains dependent on service delivery and contract performance. - The contract-asset disclosure is another useful counter-signal: the company reported no significant impairment losses on contract assets for the periods presented.

Deferred revenue primarily reflects upfront-billed service fees that are recognized as services are performed, so reported revenue and cash collection may not move in the same period. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

- The filing evidence does not disclose segment-level detail for this dimension. - The next filing should be assessed for continued year-over-year revenue and net-income growth, profitability in both reported windows, the timing of remaining performance-obligation conversion, changes in deferred revenue, bad-debt expense, and contract-asset impairment. Investors should also monitor whether hospital funding, reimbursement, staffing, inflation, tariffs, or interest-rate pressures begin to affect system demand, service activity, collections, or receivable quality.

- Risk-factor disclosure in Item 1A, market-risk disclosure in Item 3, and controls and legal-proceedings disclosure in Item 4 provide useful context for changes in these risks. No peer or industry comparison is available in the filing evidence, so the company’s performance should not be treated as evidence of relative outperformance.